The method, which is expected to aid in the early discovery of the cancer as well as minimise the risk of unnecessary surgery, may be introduced in patient care within five years, researchers said.
Pancreatic cancer is often detected at a late stage, which results in poor prognosis and limited treatment options.
The poor prognosis, where only 5 per cent of the patients survive five years after the diagnosis, is due to the fact that the tumours often develop unnoticed, and rarely cause symptoms until they have spread to other organs.
Cysts in the pancreas, which are found in every 10th person above the age of 70, and are also common in younger people, can be discovered with computed tomography (CT) or magnetic resonance imaging (MRI).
The problem is that imaging alone cannot determine which cysts are at risk for developing into cancer.
Removing the cyst by surgery, with the knowledge that it may turn out to be completely benign, is also problematic since the operation is extensive, with considerable risks for the patient.
With this method, which detects the presence of mucus protein, mucins, in the cystic fluid, the researchers were able to reach the correct diagnosis in 77 of 79 cysts that were examined.
"This is an exceptionally good result for a diagnostic test, and we are very hopeful that the method will enable more instances of early discovery of pancreatic cancer, at a stage when the cancer can be treated or prevented," said Karolina Jabbar, physician at The Sahlgrenska University Hospital.
The researchers have also tested the new method in order to analyse existing tumours and, with about 90 per cent certainty, have been able to determine which tumours have already developed into cancers.
This means that the method could also be used to determine which patients require immediate surgery, and when it is instead possible to wait and monitor the development of the cyst.
The research was published in the journal cancer.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
